Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Jun 20;115(1):2-6.
doi: 10.1161/CIRCRESAHA.114.304228.

MicroRNA-management of lipoprotein homeostasis

Xinghui Sun  1 , Mark W Feinberg  2
Affiliations
Editorial

MicroRNA-management of lipoprotein homeostasis

Xinghui Sun et al. Circ Res. .
No abstract available

Keywords: Editorials; HDL cholesterol lipoproteins; VLDL cholesterol; cardiovascular diseases; miR-33, human.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The multifaceted regulation of lipoprotein metabolism by miR-33 and the potential impact on cardiovascular disease
MiR-33 inhibition may influence HDL, VLDL-TG, and hepatic-secreted proteins to impact cardiovascular disease risk. Inhibition of miR-33 in hepatocytes leads to increased HDL synthesis and hepatic secretion of VLDL-TG and other hepatic proteins due to de-repression of ABCA1 and NSF, respectively. In macrophages, miR-33 targets ABCA1/ABCG1; however, a role for NSF as a direct target of miR-33 remains unexplored in extra-hepatic cell types. Increased VLDL-TG secretion may adversely impact CVD. Inhibition of miR-33 promotes reverse cholesterol transport in macrophages, an effect that may confer protection against CVD. Multiple factors in miR-33 inhibitor studies may account for differences observed across studies on lipoprotein metabolism and/or atherosclerosis: percentage of cholesterol in the diet, length or chemical modification of the anti-miR-33 oligonucleotides, delivery dose/route, length of treatment, and animal strains used.
See this image and copyright information in PMC

Comment on

References

    1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of ldl cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. - PMC - PubMed
    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics--2014 update: A report from the american heart association. Circulation. 2014;129:e28–e292. - PMC - PubMed
    1. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC. Hdl cholesterol, very low levels of ldl cholesterol, and cardiovascular events. The New England journal of medicine. 2007;357:1301–1310. - PubMed
    1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective american studies. Circulation. 1989;79:8–15. - PubMed
    1. Rye KA, Barter PJ. Regulation of high-density lipoprotein metabolism. Circulation research. 2014;114:143–156. - PubMed

LinkOut - more resources